ACET
Price
$0.60
Change
-$0.02 (-3.23%)
Updated
Aug 11 closing price
Capitalization
49.33M
85 days until earnings call
PCRX
Price
$25.22
Change
+$0.03 (+0.12%)
Updated
Aug 12, 12:06 PM (EDT)
Capitalization
1.13B
79 days until earnings call
Interact to see
Advertisement

ACET vs PCRX

Header iconACET vs PCRX Comparison
Open Charts ACET vs PCRXBanner chart's image
Adicet Bio
Price$0.60
Change-$0.02 (-3.23%)
Volume$1.72M
Capitalization49.33M
Pacira BioSciences
Price$25.22
Change+$0.03 (+0.12%)
Volume$700
Capitalization1.13B
ACET vs PCRX Comparison Chart in %
Loading...
ACET
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACET vs. PCRX commentary
Aug 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACET is a StrongBuy and PCRX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 12, 2025
Stock price -- (ACET: $0.60 vs. PCRX: $25.18)
Brand notoriety: ACET and PCRX are both not notable
ACET represents the Biotechnology, while PCRX is part of the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ACET: 392% vs. PCRX: 79%
Market capitalization -- ACET: $49.33M vs. PCRX: $1.13B
ACET [@Biotechnology] is valued at $49.33M. PCRX’s [@Pharmaceuticals: Generic] market capitalization is $1.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $96.01B to $0. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $66.04B to $0. The average market capitalization across the [@Biotechnology] industry is $1.79B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.64B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACET’s FA Score shows that 2 FA rating(s) are green whilePCRX’s FA Score has 0 green FA rating(s).

  • ACET’s FA Score: 2 green, 3 red.
  • PCRX’s FA Score: 0 green, 5 red.
According to our system of comparison, ACET is a better buy in the long-term than PCRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACET’s TA Score shows that 4 TA indicator(s) are bullish while PCRX’s TA Score has 4 bullish TA indicator(s).

  • ACET’s TA Score: 4 bullish, 6 bearish.
  • PCRX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, PCRX is a better buy in the short-term than ACET.

Price Growth

ACET (@Biotechnology) experienced а -13.28% price change this week, while PCRX (@Pharmaceuticals: Generic) price change was +9.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.16%. For the same industry, the average monthly price growth was +18.55%, and the average quarterly price growth was +17.82%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +5.61%. For the same industry, the average monthly price growth was +11.38%, and the average quarterly price growth was +81.44%.

Reported Earning Dates

ACET is expected to report earnings on Nov 05, 2025.

PCRX is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+8.16% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Generic (+5.61% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PCRX($1.13B) has a higher market cap than ACET($49.3M). PCRX YTD gains are higher at: 33.652 vs. ACET (-38.004). PCRX has higher annual earnings (EBITDA): 28M vs. ACET (-110.82M). PCRX has more cash in the bank: 494M vs. ACET (150M). ACET has less debt than PCRX: ACET (16.2M) vs PCRX (636M). PCRX has higher revenues than ACET: PCRX (703M) vs ACET (0).
ACETPCRXACET / PCRX
Capitalization49.3M1.13B4%
EBITDA-110.82M28M-396%
Gain YTD-38.00433.652-113%
P/E RatioN/A12.90-
Revenue0703M-
Total Cash150M494M30%
Total Debt16.2M636M3%
FUNDAMENTALS RATINGS
ACET vs PCRX: Fundamental Ratings
ACET
PCRX
OUTLOOK RATING
1..100
527
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
57
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
8941
P/E GROWTH RATING
1..100
19100
SEASONALITY SCORE
1..100
7585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACET's Valuation (30) in the Medical Distributors industry is in the same range as PCRX (57) in the Pharmaceuticals Other industry. This means that ACET’s stock grew similarly to PCRX’s over the last 12 months.

ACET's Profit vs Risk Rating (100) in the Medical Distributors industry is in the same range as PCRX (100) in the Pharmaceuticals Other industry. This means that ACET’s stock grew similarly to PCRX’s over the last 12 months.

PCRX's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as ACET (97) in the Medical Distributors industry. This means that PCRX’s stock grew similarly to ACET’s over the last 12 months.

PCRX's Price Growth Rating (41) in the Pharmaceuticals Other industry is somewhat better than the same rating for ACET (89) in the Medical Distributors industry. This means that PCRX’s stock grew somewhat faster than ACET’s over the last 12 months.

ACET's P/E Growth Rating (19) in the Medical Distributors industry is significantly better than the same rating for PCRX (100) in the Pharmaceuticals Other industry. This means that ACET’s stock grew significantly faster than PCRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACETPCRX
RSI
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
67%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
72%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
64%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
58%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
65%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
69%
Advances
ODDS (%)
Bullish Trend 8 days ago
82%
Bullish Trend 5 days ago
68%
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 7 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
70%
Bearish Trend 1 day ago
78%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
ACET
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HDVTX12.57N/A
N/A
Hartford International Equity R5
NBPTX48.85N/A
N/A
Neuberger Berman Large Cap Value Tr
JIGZX88.10N/A
N/A
JPMorgan U.S. GARP Equity R2
MSJIX19.53N/A
N/A
Morgan Stanley Global Endurance I
JYEBX11.85N/A
N/A
JHancock Real Estate Securities A

ACET and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACET has been loosely correlated with SYRE. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ACET jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACET
1D Price
Change %
ACET100%
-3.96%
SYRE - ACET
42%
Loosely correlated
+0.07%
OGI - ACET
41%
Loosely correlated
+13.15%
RGNX - ACET
41%
Loosely correlated
-4.97%
IPSC - ACET
41%
Loosely correlated
-3.84%
ARWR - ACET
40%
Loosely correlated
+4.81%
More

PCRX and

Correlation & Price change

A.I.dvisor tells us that PCRX and ELAN have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PCRX and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PCRX
1D Price
Change %
PCRX100%
N/A
ELAN - PCRX
32%
Poorly correlated
+2.58%
TEVA - PCRX
28%
Poorly correlated
+0.31%
ACET - PCRX
27%
Poorly correlated
-3.96%
SNDL - PCRX
26%
Poorly correlated
+19.64%
NBIX - PCRX
25%
Poorly correlated
-0.84%
More